Table 2.
Baseline comparison of distribution and risk factors for 119 patients who underwent LTx according to HLA-E genotypes.
| E∗01:01/∗01:01 | E∗01:01/∗01:03 | E∗01:03/∗01:03 | p | E∗01:01/∗01:01 | E∗01:03 allele | p | |
|---|---|---|---|---|---|---|---|
| Genotypes frequency (N, %) | 38 (31.9) | 57 (47.9) | 24 (20.2) | 38 (31.9) | 81 (68.1) | ||
| Male (N, %) | 15 (40) | 28 (49) | 12 (50) | 0.60 | 15 (39.5) | 40 (49) | 0.33 |
| Age of recipient (SD) | 39.1 (14.2) | 40.23 (13) | 39.6 (12) | 0.92 | 39.1 (14.2) | 40 (13) | 0.72 |
| Initial disease | 0.33 | 0.91 | |||||
| Emphysema (N, %) | 10 (26.3) | 11 (19.3) | 10 (41.7) | 10 (26.3) | 21 (25.9) | ||
| Fibrosis (N, %) | 8 (21.1) | 8 (14) | 5 (20.8) | 8 (21.1) | 13 (16.1) | ||
| Cystic fibrosis (N, %) | 14 (36.8) | 28 (49.1%) | 6 (25%) | 14 (36.8) | 34 (42.1) | ||
| Others (N, %) | 6 (15.8) | 10 (17.5%) | 3 (12.5) | 6 (15.8) | 13 (16) | ||
| Transplant procedure | 0.58 | 0.92 | |||||
| Lung and heart transplantation (N, %) | 1 (2.6) | 0 (0) | 1 (4.2) | 1 (2.6) | 1 (1.2) | ||
| Single lung transplantation (N, %) | 8 (21.1) | 14 (24.6) | 4 (16.7) | 8 (21.1) | 18 (22.2) | ||
| Bilateral lung transplantation (N, %) | 29 (76.3) | 43 (75.4) | 19 (79.2) | 29 (76.3) | 62 (76.5) | ||
| CMV status | |||||||
| D+/R− (N, %) | 6 (16.2) | 7 (12.3) | 4 (17.4) | 0.83 | 6 (16.2) | 11 (13.8) | 0.78 |
| D+/R+ or − (N, %) | 19 (51) | 31 (54) | 9 (40) | 0.46 | 19 (51) | 40 (50) | 0.88 |
| D+ or −/R+ (N, %) | 22 (58) | 36 (63) | 12 (50) | 0.54 | 22 (58) | 48 (59) | 0.88 |
| Mismatch HLA/6 (N) | 5.03 | 5 | 4.83 | 0.9 | 5.03 | 4.95 | 0.90 |
| Infection at M1 (N, %) | 8 (53.3) | 16 (47.1%) | 2 (25) | 0.49 | 8 (53.3) | 18 (42.9) | 0.48 |
| Infection at M3 (N, %) | 6 (46.2) | 7 (38.9) | 5 (50) | 0.83 | 6 (46.2) | 12 (42.9) | 0.84 |
| Infection in first year (N, %) | 16 (42) | 32 (56) | 11 (45.8) | 0.37 | 16 (42.1) | 43 (53.1) | 0.26 |
| DSA at M1 (N, %) | 7 (63.6) | 13 (81.3) | 5 (83.3) | 0.51 | 7 (63.5) | 18 (81.8) | 0.25 |
| DSA at M3 (N, %) | 6 (66.7) | 8 (66) | 3 (60) | 1 | 6 (66.7) | 11 (64.7) | 0.92 |
| CLAD occurrence (N, %) | 5 (22.7) | 20 (40.8) | 7 (58.3) | 0.06 | 5 (22.7) | 27 (44.3) | 0.02 |
| BOS (N, %) | 5 (23.8) | 16 (32.7) | 6 (22.2) | 0.31 | 5 (23.8) | 22 (36.1) | 0.02 |
| RAS (N, %) | 0 (0) | 4 (8.2) | 1 (8.3) | 0.41 | 0 (0) | 5 (8.2) | 0.32 |
| Overall survival (median, year) | 2.37 | 3.7 | 2.6 | 0.01 |